Carisma Therapeutics 경영진

경영진 기준 점검 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

핵심 정보

최고경영자

n/a

총 보수

CEO 급여 비율	n/a
CEO 재임 기간	no data
CEO 지분 보유율	n/a
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	3.3yrs

최근 경영진 업데이트

Recent updates

분석 기사 • Mar 28

Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Business And Shares Still Trailing The Industry

You may think that with a price-to-sales (or "P/S") ratio of 0.7x Carisma Therapeutics, Inc. ( NASDAQ:CARM ) is...

분석 기사 • Dec 06

Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 28%

Carisma Therapeutics, Inc. ( NASDAQ:CARM ) shares have had a horrible month, losing 28% after a relatively good period...

분석 기사 • Sep 02

Companies Like Carisma Therapeutics (NASDAQ:CARM) Could Be Quite Risky

We can readily understand why investors are attracted to unprofitable companies. For example, although...

분석 기사 • May 12

US$8.40: That's What Analysts Think Carisma Therapeutics, Inc. (NASDAQ:CARM) Is Worth After Its Latest Results

Carisma Therapeutics, Inc. ( NASDAQ:CARM ) just released its latest quarterly report and things are not looking great...

분석 기사 • Apr 19

Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 26%

The Carisma Therapeutics, Inc. ( NASDAQ:CARM ) share price has fared very poorly over the last month, falling by a...

분석 기사 • Mar 26

We're A Little Worried About Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

분석 기사 • Jan 21

Lacklustre Performance Is Driving Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 26% Price Drop

Carisma Therapeutics, Inc. ( NASDAQ:CARM ) shareholders won't be pleased to see that the share price has had a very...

분석 기사 • Dec 07

The Market Doesn't Like What It Sees From Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Revenues Yet As Shares Tumble 27%

To the annoyance of some shareholders, Carisma Therapeutics, Inc. ( NASDAQ:CARM ) shares are down a considerable 27% in...

분석 기사 • Nov 12

Analyst Forecasts Just Became More Bearish On Carisma Therapeutics, Inc. (NASDAQ:CARM)

The analysts covering Carisma Therapeutics, Inc. ( NASDAQ:CARM ) delivered a dose of negativity to shareholders today...

분석 기사 • Oct 05

Here's Why We're Watching Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...

분석 기사 • Jun 15

We're Hopeful That Carisma Therapeutics (NASDAQ:CARM) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

CEO

Carisma Therapeutics에는 CEO가 없거나 해당 데이터가 없습니다.

이사회 구성원

이름	직위	재임 기간	보수	지분
Saar Gill	Co-Founder & Chairman of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Sanford Zweifach	Independent Chairman of the Board	3.3yrs	US$143.23k	0.00099% $ 3.3
Hyam Levitsky	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Carl June	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Nina Bhardwaj	Member of Scientific Advisory Board	5.9yrs	데이터 없음	데이터 없음
Steven Kelly	Director	3.3yrs	US$1.72m	0% $ 0
Scott L. Friedman	Member of Scientific Advisory Board	1.8yrs	데이터 없음	데이터 없음
Marella Thorell	Independent Director	2yrs	US$81.48k	0% $ 0
Lisa Coussens	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Prasad Adusumilli	Member of Scientific Advisory Board	5.9yrs	데이터 없음	데이터 없음
Sohanya Cheng	Independent Director	1.7yrs	US$39.29k	0% $ 0
Lin Guey	Member of Scientific Advisory Board	3.3yrs	데이터 없음	데이터 없음

3.3yrs

평균 재임 기간

64.5yo

평균 나이

경험이 풍부한 이사회: CARM의 이사회는 경험이 있음으로 간주됩니다(평균 재임 3.3 년).

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/06/24 19:50
종가	2026/06/24 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Carisma Therapeutics, Inc.는 5명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Justin Zelin	BTIG
Suranjit Mukherjee	BTIG
Naureen Quibria	Capital One Securities, Inc.

Carisma Therapeutics 경영진

경영진 기준 점검 1/4

핵심 정보

최근 경영진 업데이트

High number of new and inexperienced directors

Carisma Therapeutics, Inc. Announces Leaving of Richard Morris as Chief Financial Officer, Effective December 31, 2024

Carisma Therapeutics Announces Changes to Its Board of Directors

Carisma Therapeutics, Inc. Announces Appointments of Its Scientific Advisory Board

Carisma Therapeutics, Inc. Announces Board Changes

Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer

Recent updates

Carisma Therapeutics Files Form 15

Carisma Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

Carisma Therapeutics Notifies Nasdaq of the Company’s Intention to File a Form 25 with the Sec on or About December 10, 2025 to Effect the Formal Delisting of the Common Stock

Carisma Therapeutics, Inc.(NasdaqCM:CARM) dropped from S&P TMI Index

Carisma Therapeutics Inc Receives a Delisting Determination Letter from the Nasdaq Stock Market

New major risk - Market cap size

Second quarter 2025 earnings released: US$0.23 loss per share (vs US$0.27 loss in 2Q 2024)

New major risk - Revenue and earnings growth

Carisma Therapeutics, Inc. Provides Update on Nasdaq Non-Compliance

OrthoCellix, Inc. entered into an agreement to Carisma Therapeutics, Inc. (NasdaqCM:CARM) in a reverse merger transaction.

High number of new and inexperienced directors

Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Business And Shares Still Trailing The Industry

Carisma Therapeutics Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Carisma Therapeutics, Inc. Announces Leaving of Richard Morris as Chief Financial Officer, Effective December 31, 2024

Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 28%

Carisma Therapeutics Inc. Unveils Promising Pre-Clinical Data on Anti-Gpc3 in Vivo Car-M Therapy for Hepatocellular Carcinoma

Carisma Therapeutics, Inc. Announces to Present New Data on Anti-GPC3 in Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024

Carisma Therapeutics Announces Changes to Its Board of Directors

Carisma Therapeutics Receives Written Notice from Nasdaq Regarding Non- Compliance with the Minimum Market Value of Listed Securities Requirement under Nasdaq Listing Rule 5450(b)(2)(A)

Carisma Therapeutics, Inc.(NasdaqGM:CARM) dropped from S&P Global BMI Index

Companies Like Carisma Therapeutics (NASDAQ:CARM) Could Be Quite Risky

Carisma Therapeutics, Inc. Announces Appointments of Its Scientific Advisory Board

Carisma Therapeutics, Inc.(NasdaqGM:CARM) dropped from Russell 3000 Index

Carisma Therapeutics, Inc. Announces Board Changes

Carisma Therapeutics, Inc. Grants FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors

New major risk - Revenue and earnings growth

Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, A Novel HER2-Targeting CAR-Monocyte

US$8.40: That's What Analysts Think Carisma Therapeutics, Inc. (NASDAQ:CARM) Is Worth After Its Latest Results

First quarter 2024 earnings released: US$0.46 loss per share (vs US$1.93 loss in 1Q 2023)

Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer

Carisma Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 26%

Price target decreased by 12% to US$8.40

Consensus revenue estimates increase by 107%

Price target decreased by 7.7% to US$9.00

Carisma Therapeutics, Inc. Announces Changes to Its Board of Directors

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

We're A Little Worried About Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Rate

Lacklustre Performance Is Driving Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 26% Price Drop

New minor risk - Market cap size

The Market Doesn't Like What It Sees From Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Revenues Yet As Shares Tumble 27%

Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte

Consensus revenue estimates increase by 41%, EPS downgraded

Analyst Forecasts Just Became More Bearish On Carisma Therapeutics, Inc. (NASDAQ:CARM)

New minor risk - Market cap size

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Carisma Therapeutics Inc. to Present First Results from in Vivo Car-M Collaboration with Moderna at SITC 2023

Here's Why We're Watching Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Situation

Carisma Therapeutics, Inc. Announces Latest Data from Phase 1 Clinical Trial of CT-0508 At 8th Annual CAR-TCR Summit

Carisma Therapeutics Announces First Patient Dosed in Phase 1 Study of CT-0508 in Combination with Keytruda(R) (Pembrolizumab) in Patients with Her2 Overexpressing Solid Tumors

New major risk - Share price stability

Carisma Therapeutics Inc. Appoints Eric Siegel as General Counsel and Corporate Secretary and Terry Shields as Senior Vice President of Human Resources